相关实验视频

Updated: Jul 10, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

双重向的石墨级联纳米酶用于识别和治疗Helicobacter pylori

Hui Deng¹, Yi Zhang¹, Xinqi Cai¹

¹Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, 410082, China.

Small (Weinheim an der Bergstrasse, Germany)

|November 22, 2023

概括

一种新型的双重向纳米酶,PtCo@Graphene@Hemin-2(L-arginine),通过克服胃酸挑战,有效治疗Helicobacter pylori感染. 这一策略显著提高了H. pylori在酸性胃环境中的向和根除.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
传染病治疗方法传染病治疗方法

背景情况:

杆菌 (H. pylori) 是胃疾病的主要原因.
目前的H. pylori治疗面临挑战,因为药物被胃酸和素降解.

研究的目的:

设计一个双目标级联催化纳米酶,用于增强 H. pylori 治疗.
克服胃环境中现有的治疗方法的局限性.

主要方法:

开发PtCo@Graphene@Hemin-2(L-氨酸) (PtCo@G@H2A) 纳米酶的研究.
采用血红素用于直接准H. pylori受体,并使用L-氨酸用于酸触发的电荷逆转和捕获.
通过反应性氧物种 (ROS) 来研究氧化物 (NO) 生产的pH响应性氧化酶类活性.

主要成果:

与单一向相比,双重向策略将H. pylori向率提高了850%,而单一向策略则提高了850%.
在模拟的肠液 (NaHCO3) 中,PtCo@G@H2A 证明了快速地恢复表面潜力,以防止副作用.
该纳米酶通过一连串的催化过程产生NO.表现出酸选择性杀菌作用.

结论:

PtCo@G@H2A为H. pylori治疗提供了一个有前途的策略,在酸性胃状况下保持高向性和治疗疗效.
纳米酶的双重向和pH响应的催化特性代表了对抗H. pylori感染的重大进步.

关键词:

在Helicobacter Pylori的研究中,级联的纳米酶级联.电荷逆转可以改变电荷.这是一个双重目标.氧化氧化的使用方法

更多相关视频

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.